Trials / Completed
CompletedNCT04552197
A Study of JNJ-64251330 in Healthy Participants
A Phase 1, Open-Label, Multi-Dose Study to Assess the Systemic and Local Tissue Pharmacokinetics and Pharmacodynamics of JNJ-64251330 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate: systemic and local gut (rectum and sigmoid colon) exposure to JNJ-64251330, local tissue Pharmacodynamics (PD) using gut (rectum and sigmoid colon) biopsies (Part 1) and the effect of food on the rate and extent of absorption of JNJ-64251330 from oral tablet dosed with or without food (Part 2).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-64251330 | JNJ-64251330 tablet will be administered orally. |
| DRUG | Tofacitinib | Tofacitinib tablets will be administered orally. |
Timeline
- Start date
- 2020-09-02
- Primary completion
- 2020-12-29
- Completion
- 2020-12-29
- First posted
- 2020-09-17
- Last updated
- 2022-12-02
Locations
1 site across 1 country: Belgium
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04552197. Inclusion in this directory is not an endorsement.